

ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/
Form 10-Q
November 10, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 10-Q

Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2010 or

Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _____ to _____

001-9731
(Commission file No.)

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of incorporation
or organization)

72-0925679
(I.R.S. employer identification no.)

25 Sawyer Passway
Fitchburg, Massachusetts 01420
(Address of principal executive offices)

(978) 345-5000
(Registrant's telephone number, including area code)

Check whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No .

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated filer [] Accelerated filer [] Non-Accelerated filer [] Smaller reporting company []

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 10, 2010 there were 2,790,514 shares of the Company's common stock outstanding.

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

TABLE OF CONTENTS

FORM 10-Q

September 30, 2010

PART I - FINANCIAL INFORMATION

| | |
|---|----|
| <u>Item 1. Consolidated Financial Statements</u> | 1 |
| <u>Consolidated Balance Sheets</u> | 1 |
| <u>Consolidated Statements of Income</u> | 2 |
| <u>Consolidated Statements of Cash Flows</u> | 3 |
| Consolidated Statements of Changes in <u>Stockholders' Equity and Comprehensive</u> | 4 |
| <u>Income</u> | |
| <u>Notes to the Consolidated Financial Statements</u> | 5 |
| <u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of</u> | 8 |
| <u>Operations</u> | |
| <u>Item 3. Quantitative and Qualitative Disclosure About Market Risks</u> | 13 |
| <u>Item 4. Controls and Procedures</u> | 13 |

PART II - OTHER INFORMATION

| | |
|-------------------------|----|
| <u>Item 7. Exhibits</u> | 14 |
|-------------------------|----|

SIGNATURES

| | |
|--|-----|
| <u>Exhibit 31.1 Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</u> | X-1 |
| <u>Exhibit 31.2 Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</u> | X-2 |
| <u>Exhibit 32.1 Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002</u> | X-3 |
| <u>Exhibit 32.2 Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002</u> | X-4 |

PART I - FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY

Consolidated Balance Sheets

| ASSETS | September 30, 2010 (Unaudited) | December 31, 2009 (Audited) |
|--|---|--------------------------------------|
| Current assets: | | |
| Cash and cash equivalents | \$3,139,546 | \$3,674,179 |
| Trade and other accounts receivable, net of allowance for doubtful accounts of \$68,976 and \$49,976 | 4,128,076 | 3,818,538 |
| Inventories, net | 3,147,652 | 2,956,682 |
| Deferred income taxes, net | 51,800 | 22,500 |
| Prepaid tax | 49,289 | 123,789 |
| Deposits, prepaid expenses and other current assets | 528,168 | 147,243 |
| Total current assets | 11,044,531 | 10,742,931 |
| Property and equipment, net of accumulated depreciation of \$11,276,128 and \$10,361,928 | 6,470,730 | 6,343,575 |
| Goodwill | 1,564,966 | 1,564,966 |
| Restricted cash | 515,562 | - |
| Other intangible assets, net | 80,064 | 95,887 |
| Total assets | \$19,675,853 | \$18,747,359 |

LIABILITIES AND SHAREHOLDERS' EQUITY

| | | |
|--|-------------|-------------|
| Current liabilities: | | |
| Accounts payable | \$1,649,157 | \$1,543,700 |
| Accrued expenses and customer deposits | 571,145 | 276,903 |
| Total current liabilities | 2,220,302 | 1,820,603 |

| | | |
|--|--------------|--------------|
| Long term liabilities: | | |
| Long term deferred tax liability, net | 130,066 | 350,000 |
| Long term portion of deferred gain on lease | 18,985 | 22,347 |
| Total long term liabilities | 149,051 | 372,347 |
| Total liabilities | 2,369,353 | 2,192,950 |
| Shareholders' equity: | | |
| Preferred stock, \$1 par value; 2,000,000 shares authorized, none issued | - | - |
| Common stock, \$0.01 par value; 10,000,000 shares authorized, 3,926,491 shares issued, 2,790,514 and 2,675,481 outstanding | 39,265 | 39,265 |
| Additional paid-in-capital | 10,633,095 | 10,317,403 |
| Common stock held in treasury, 1,135,977 and 1,251,010 shares at cost | (3,099,842) | (3,413,742) |
| Retained earnings | 9,715,848 | 9,611,483 |
| Accumulated other comprehensive income | 18,134 | - |
| Total shareholders' equity | 17,306,500 | 16,554,409 |
| Total liabilities and shareholders' equity | \$19,675,853 | \$18,747,359 |

The accompanying notes are an integral part of the consolidated financial statements.

ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY

Consolidated Statements of Income

(Unaudited)

| | Three months ended September 30, | | Nine months ended September 30, | |
|-----------------------------------|-------------------------------------|--------------|------------------------------------|---------------|
| | 2010 | 2009 | 2010 | 2009 |
| Revenue | \$ 5,888,277 | \$ 5,457,377 | \$ 17,255,916 | \$ 15,512,270 |
| Cost of sales | 4,605,683 | 4,576,068 | 13,894,697 | 12,811,506 |
| Gross profit | 1,282,594 | 881,309 | 3,361,219 | 2,700,764 |
| Selling and marketing | 259,831 | 173,323 | 673,457 | 507,501 |
| General and administrative | 749,396 | 509,037 | 2,025,255 | 1,596,933 |
| Research and development | 76,189 | 54,444 | 179,000 | 180,918 |
| Total expense | 1,085,416 | 736,804 | 2,877,712 | 2,285,352 |
| Income from operations | 197,178 | 144,505 | 483,507 | 415,412 |
| Other income (expense), net | (2,450) | (15,291) | 142,319 | (34,504) |
| Income before income taxes | 194,728 | 129,214 | 625,826 | 380,908 |
| Income tax provision | 75,200 | 21,000 | 185,000 | 114,000 |
| Net income | \$ 119,528 | \$ 108,214 | \$ 440,826 | \$ 266,908 |
| Net income per share – basic | \$ 0.04 | \$ 0.04 | \$ 0.16 | \$ 0.10 |
| Net income per share – diluted | \$ 0.04 | \$ 0.04 | \$ 0.16 | \$ 0.10 |
| Dividend declared per share | \$ 0.06 | \$ - | \$ 0.12 | \$ - |
| Weighted average common shares | | | | |
| Outstanding – basic | 2,790,514 | 2,675,481 | 2,719,724 | 2,679,371 |
| Weighted average common shares | | | | |
| Outstanding – diluted | 2,820,834 | 2,675,481 | 2,769,049 | 2,679,371 |

The accompanying notes are an integral part of the consolidated financial statements.

ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY

Consolidated Statements of Cash Flows

(Unaudited)

| | Nine months Ended September 30, | |
|---|------------------------------------|--------------|
| | 2010 | 2009 |
| Cash flows from operating activities: | | |
| Net income | \$ 440,826 | \$ 266,908 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Noncash gain from bargain purchase | (146,288) | - |
| Depreciation and amortization | 1,070,175 | 1,049,113 |
| Share based compensation | 79,041 | 56,260 |
| Provision for doubtful accounts | 19,000 | 1,463 |
| Deferred tax expense | (84,000) | 114,000 |
| Changes in operating assets and liabilities: | | |
| Trade and other accounts receivable | (328,538) | (767,782) |
| Inventories | (190,970) | 465,078 |
| Deposits, prepaid expenses and other assets | (325,575) | 61,031 |
| Accounts payable and accrued expenses | 314,084 | 443,307 |
| Net cash provided by operating activities | 847,755 | 1,689,378 |
| Cash flows from investing activities: | | |
| Capital expenditures, net of disposals | (1,080,418) | (818,701) |
| Acquisition activities | 16,357 | - |
| Net cash used in investing activities | (1,064,061) | (818,701) |
| Cash flows from financing activities: | | |
| Payments on note payable | - | (638,091) |
| Cash dividend paid | (336,461) | - |
| Purchase of treasury shares | - | (33,188) |
| Net cash used in financing activities | (336,461) | (671,279) |
| Effect of foreign exchange on cash and cash equivalents | | |
| | 18,134 | - |
| Net increase or (decrease) in cash and cash equivalents | (534,633) | 199,398 |
| Cash and cash equivalents at beginning of period | 3,674,179 | 2,320,467 |
| | \$ 3,139,546 | \$ 2,519,865 |

Cash and cash equivalents at end of
period

The accompanying notes are an integral part of the consolidated financial statements.

ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY

Consolidated Statements of Changes in
Stockholders' Equity and Comprehensive Income

(Unaudited)

| | Common Stock Shares | Common Stock Amount | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Other comprehensive income | Totals | Comprehensive Income |
|---|------------------------|------------------------|----------------------------------|-------------------|----------------------|----------------------------------|--------------|-------------------------|
| December 31, 2009 | 3,926,491 | \$39,265 | \$10,317,403 | \$(3,413,742) | \$9,611,483 | \$- | \$16,554,409 | \$- |
| Treasury shares issued | - | - | 144,678 | 313,900 | - | - | 458,578 | - |
| Options issued for business combination activities | - | - | 79,041 | - | - | - | 79,041 | - |
| Share based compensation | - | - | 91,973 | - | - | - | 91,973 | - |
| Foreign currency translation adjustments | - | - | - | - | - | 18,134 | 18,134 | 18,134 |
| Cash dividends | - | - | - | - | (336,461) | - | (336,461) | - |
| Net income | - | - | - | - | 440,826 | - | 440,826 | 440,826 |
| Comprehensive Income | - | - | - | - | - | - | - | \$458,960 |
| September 30, 2010 | 3,926,491 | \$39,265 | \$10,633,095 | \$(3,099,842) | \$9,715,848 | \$18,134 | \$17,306,500 | |

The accompanying notes are an integral part of the consolidated financial statements.

Notes to the Consolidated Financial Statements

1. Basis of Presentation:

The unaudited interim consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and notes thereto included in the Arrhythmia Research Technology, Inc. and subsidiary (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2009 filed March 10, 2010.

The information presented reflects, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial results for the interim period presented.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Operating results for interim periods are not necessarily indicative of results that may be expected for the entire fiscal year.

2. Inventories:

| | September 30, 2010 | December 31, 2009 |
|---|--------------------------|----------------------|
| Inventories consist of the following as of: | | |
| Raw materials | \$ 993,208 | \$ 1,043,228 |
| Work-in-process | 312,562 | 243,360 |
| Finished goods | 1,841,882 | 1,679,094 |
| Total | \$ 3,147,652 | \$ 2,956,682 |

3. Share-Based Compensation:

The Company accounts for non-cash share based compensation under ASC 718 “Stock Compensation”, which establishes accounting for equity instruments exchanged for employee services. Under the provisions of ASC 718, share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).

The Company estimates the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. The Company believes that the valuation technique and the approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of the Company’s stock options. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

The following assumptions were used to estimate the fair market value of options granted using the Black Scholes valuation method:

| | Nine months Ended September 30, 2010 |
|-------------------------------------|---|
| Dividend Yield | 1.26% |
| Expected Volatility | 46.48% |
| Risk Free Interest Rate | 1.2% |
| Expected Option Terms (in years) | 5.0 |

The Company recognized share-based compensation expense of \$22,030 and \$19,490 in general and administrative expense for the three months ended September 30, 2010 and 2009, respectively, and \$79,041 and \$56,260 in general and administrative expense for the nine months ended September 30, 2010 and 2009, respectively. Outside of the Company's stock option plan, a grant totaling 60,000 non-qualified options was made in conjunction with business combination activities on June 18, 2010. One third of this grant became vested in October 2010 as the first performance target was met. No grants were made in the first nine months of 2009.

Share-based Incentive Plan

At September 30, 2010, the Company has one stock option plan that includes both incentive stock options and non-statutory stock options to be granted to certain eligible employees, non-employee directors, or consultants of the Company. The maximum number of shares reserved for issuance is 500,000 shares. The options granted have six-year contractual terms and either vest immediately or vest annually over a five-year term.

At September 30, 2010, there were 500,000 shares available for future grants under the above stock option plan. The weighted average exercise price of options outstanding was \$7.55 at September 30, 2010.

The following table presents the average price and contractual life information about plan and non-plan options outstanding and exercisable under the stock option plan and in conjunction with business combination activities at September 30, 2010:

| Exercise Price | Number of Outstanding Shares | Weighted Average Remaining Contractual Life (years) | Options Currently Exercisable | Average Fair Value at Grant Date |
|----------------|------------------------------|---|-------------------------------|----------------------------------|
| \$ 3.41 | 75,500 | 5.26 | -- | \$ 0.96 |
| 4.76 | 60,000 | 4.71 | -- | 1.77 |
| 7.15 | 96,000 | 3.26 | 38,400 | 2.74 |
| 9.86 | 63,000 | 1.22 | 63,000 | 4.22 |
| 12.42 | 10,000 | 1.85 | 6,000 | 5.38 |
| 23.10 | 10,000 | 2.43 | 6,000 | 10.77 |

The aggregated intrinsic value of options outstanding and vested at September 30, 2010 was \$276,720 and \$0, respectively. The Company expects 157,341 of the 201,100 options to vest over their remaining life.

The following table summarizes the activity of Company's non-vested options since December 31, 2009:

| | Number of Shares | Non-Vested Options Weighted Average Fair Value |
|----------------------------------|------------------|--|
| Non-vested at December 31, 2009 | 86,800 | \$ 3.42 |
| Granted | 135,500 | 1.32 |
| Vested | (21,200) | 3.50 |
| Forfeited | - | - |
| Non-vested at September 30, 2010 | 201,100 | \$ 2.00 |

At September 30, 2010, there was \$214,912 of total unrecognized cost related to non-vested share-based compensation arrangements granted under the Plan. This cost is expected to be recognized over a weighted average period of 3.68 years.

4. Business Combination Activities:

On June 18, 2010, the Company through a newly created Delaware subsidiary named RMDDxUSA Corp. purchased all of the outstanding shares of RMDDx Corporation (“RMDDx”), a Prince Edward Island corporation. The shares were exchanged for 115,033 shares of ART common stock and options to purchase 60,000 shares at \$4.76. These shares and options were immediately placed in escrow and are released and vested based upon the achievement of certain performance targets. The performance targets require client contracts, service volumes and gross sales with minimum gross margins.

RMDDxUSA Corp. is the U.S. sales and distribution operations entity for and parent of RMDDx.

RMDDx is a medical device and diagnostic service company dedicated to the development and commercialization of medical devices, medical information technology, medical diagnostics and patient monitoring through wireless, internet and telecommunication technologies. Since inception, the efforts have been devoted to the development of remote wireless medical technology for heart monitors. To date, RMDDx had no revenues.

The fair value of the assets acquired and liabilities assumed in the acquisition on June 18, 2010 is as follows:

| | |
|---------------------|------------|
| Assets | |
| Current Assets | \$ 17,357 |
| Fixed Assets | 83,381 |
| Deferred Tax Assets | 165,872 |
| Other Assets | 512,483 |
| Total Assets | \$ 779,093 |
| Liabilities | |
| Current Liabilities | \$ 82,254 |
| Total Liabilities | \$ 82,254 |

RMDDx has a deferred tax asset related to losses prior to the close of the transaction. The deferred tax asset is for Canadian and Provincial corporate income taxes. A valuation allowance of 20% was applied to the tax asset based on projected ability to utilize the tax benefit in the time allowed. If in the future this valuation allowance is reduced, the tax expense of RMDDx will be reduced for that period.

At September 30, 2010, RMDDx has \$515,562 in cash which is restricted as it collateralizes a guarantee on a stand-by letter of credit related to a Canadian Federal contracting economic incentive program involving an unrelated third party. Using the judgments of management in the fair market valuation required by ASC 805 "Business Combinations", over the next 5 years the targets of the incentive program are expected to be achieved. These calculations and the associated assumptions are the basis for not including a contingent liability related to the guarantee. Any time before the period ends, RMDDx has the right to issue its own guarantee and remove the restriction currently on the cash. The Province of Prince Edward Island (the Province), through an economic incentive program, has committed expense reimbursements up to \$585,000 to the company in the form of a labor and equipment rebate. No material rebate has been earned prior to the acquisition.

The common stock was issued from treasury, and the options were issued outside of the Company's existing stock option plan. The fair value of the options was determined by using the Black Scholes valuation methods described in Note 3. The fair value of the equity issued was determined based on the probability of the management of RMDDx meeting the performance targets required for the release and vesting of shares and options. In compliance with ASC 805-30-30-1, a fair value of the equity was determined to be \$550,551 and was calculated by discounting the targets outside of a 12 month period with an estimate of the probability of attainment. The determination of probabilities was made using the same assumptions used throughout the purchase accounting.

In compliance with 805-30-25-2, this transaction was deemed a "bargain purchase" with the resulting gain of \$146,288 booked as other income in the quarter ended June 30, 2010. This increase to other income offsets the general and administrative costs related to the transaction of approximately \$80,000 in the same period. As defined by FASB ASC 805-30-25, the purchase of RMDDx was not a forced sale in which the seller acted under compulsion. The discount to fair value relates to sellers belief in the future value of the combined entity exceeding the current value of the consideration.

5. Income Taxes:

The Company accounts for income taxes in accordance with ASC 740 "Income Taxes," which requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the

difference between the financial statement and tax bases of assets and liabilities using tax rates in effect for the year in which the differences are expected to reverse.

The Company files income tax returns in the U.S. Federal jurisdiction and various state jurisdictions. The periods from 2007 to 2009 remain open to examination by the IRS and state jurisdictions. The Company believes it is not subject to any significant tax risk. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits, nor were any interest expenses recognized during the nine months ended September 30, 2009 and 2010.

6. Earnings per share:

In accordance with ASC 260, the basic earnings per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were dilutive. At September 30, 2010, 179,000 of the stock options were anti-dilutive and excluded in the earnings per share computation.

7. Recent Accounting Pronouncements:

In October 2009, the FASB issued Accounting Standards Update (“ASU”) No. 2009-13, “Multiple-Deliverable Revenue Arrangements” (“ASU 2009-13”). ASU 2009-13 establishes the accounting and reporting guidance for arrangements including multiple revenue-generating activities, and provides amendments to the criteria for separating deliverables, measuring and allocating arrangement consideration to one or more units of accounting. The amendments in ASU 2009-13 also establish a selling price hierarchy for determining the selling price of a deliverable. Significantly enhanced disclosures are also required to provide information about a vendor’s multiple-deliverable revenue arrangements, including information about the nature and terms, significant deliverables, and its performance within arrangements. The amendments also require providing information about the significant judgments made and changes to those judgments and about how the application of the relative selling-price method affects the timing or amount of revenue recognition. The amendments in ASU 2009-13 are effective prospectively for revenue arrangements entered into or materially modified in the fiscal years beginning on or after June 15, 2010. Early application is permitted. The Company adopted ASU 2009-13, and the adoption did not have an impact on the Company’s financial position or results of operations.

In February 2010, the Financial Accounting Standards Board (“FASB”) issued an update that removes the requirement for a SEC filer to disclose a date through which subsequent events have been evaluated. This change removes potential conflicts with SEC requirements. The adoption did not have an impact on the Company’s consolidated financial statements.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Any forward looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. These statements are made under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “expect,” “anticipate,” “believe,” “intend,” “plans,” “predict,” “will”. Although the Company believes that management’s expectations are based on reasonable assumptions, the Company can give no assurance that management’s expectations will materialize. Many factors could cause actual results to differ materially from any forward looking statements. Several of these factors include, without limitation: management’s ability to maintain the current pricing model and/or decrease the cost of sales; continued availability of supplies or materials used in manufacturing at competitive prices; volatility in commodity and energy prices and management’s ability to offset higher costs with price increases; adverse regulatory developments in the U.S. or any other country the Company plans to do business in; the costs inherent with complying with new statutes and

regulations applicable to public reporting companies, such as the Sarbanes-Oxley Act of 2002; variability of customer delivery requirements; the Company's ability to efficiently integrate future acquisitions and other new lines of business that the Company may enter in the future, if any; and other risks referenced from time to time elsewhere in this report and in the Company's filings with the SEC.

The Company is under no obligation and does not intend to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2009.

Overview

Arrhythmia Research Technology, Inc. (“ART”) is engaged in the licensing of medical software, which acquires data and analyzes electrical impulses of the heart to detect and aid in the treatment of potentially lethal arrhythmias. RMDDxUSA Corp. (“RMDDx”), a wholly owned subsidiary of ART, performs US sales and distribution operations for its subsidiary, RMDDx Corporation, which was acquired in June 2010. RMDDx is a development stage organization dedicated to the development and commercialization of medical devices, medical information technology, medical diagnostics and remote patient monitoring through wireless, internet and telecommunication technologies. Micron Products, Inc. (“Micron”), a wholly owned subsidiary of ART, is the primary source of consolidated revenues. This primary source of revenue relates to the manufacturing of components, devices and equipment primarily for the medical and defense industries. The single largest product category of revenue relates to Micron’s production and sale of silver/silver chloride coated and conductive resin sensors used as component parts in the manufacture of integrated disposable electrophysiological sensors. These disposable medical devices are used worldwide in the monitoring of electrical signals in various medical applications. In an effort to leverage current skills, the Company has expanded into custom thermoplastic injection molded products and product life cycle management. This category includes revenues from both high volume precision injection molding and custom injection molding. With the addition of a medical machining cell, the Company began production of patient specific metal medical devices. Management continues to identify complementary and/or synergistic products, technologies and lines of business in an effort to broaden the Company’s offerings.

Results of Operations

Revenue for the three months ended September 30, 2010 was \$5,888,277 versus \$5,457,377 for the three months ended September 30, 2009, an increase of 7.9%. Revenues related to licensing of the Company’s SAECG product accounted for \$200,000 in the three months ended September 30, 2010. Micron’s medical sensors and snaps with silver surcharge revenue increased by \$586,000 and high volume precision molded products and other miscellaneous sales increased by \$47,000. The increase in revenues from sensors and snaps is due to increased volume in sensors and higher silver surcharge. Revenue from the Micron Integrated Technology’s (MIT) product life cycle management programs decreased \$402,000. MIT’s revenue is derived from the custom molding, precision metal machining and mold making activities. The revenue declines reflect timing delays with a defense industry product line and medical molding and precision machining partially offset by increases in tooling sales. RMDDx did not contribute to revenues for the three months ended September 30, 2010.

Revenue for the nine months ended September 30, 2010 was \$17,255,916 versus \$15,512,270 for the nine months ended September 30, 2009, an increase of 11%. Revenues related to the customization and licensing of the Company’s SAECG product accounted for \$300,000 in the nine months ended September 30, 2010. Micron’s medical sensors and snaps with silver surcharge revenue increased by \$1,794,000 and high volume precision molded products and other miscellaneous sales increased by \$32,000. The increase in revenues from sensors and snaps is due to increased volume in sensors and higher silver surcharge. Revenue from the Micron Integrated Technology’s (MIT) product life cycle management programs decreased \$382,000. MIT’s revenue is derived from the custom molding, precision metal machining and mold making activities. The revenue decreases reflect lower volume of defense industry products and tooling sales partially offset by an increase in custom molded and precision machined medical products. RMDDx did not contribute to revenues for the nine months ended September 30, 2010.

Revenue from domestic and foreign sales for the three and nine month period is as follows:

| Three Months Ending September 30, | | | | Nine months Ending September 30, | | | |
|-----------------------------------|---|------|---|----------------------------------|---|------|---|
| 2010 | % | 2009 | % | 2010 | % | 2009 | % |

| | | | | | | | | |
|---------------|-------------|-----|-------------|-----|--------------|-----|--------------|-----|
| United States | \$3,119,155 | 53 | \$3,620,010 | 66 | \$9,158,010 | 53 | \$9,741,678 | 63 |
| Canada | 1,373,442 | 23 | 865,622 | 16 | 4,128,142 | 24 | 2,685,721 | 17 |
| Europe | 608,331 | 10 | 678,763 | 13 | 1,753,490 | 10 | 2,051,400 | 13 |
| Pacific Rim | 677,297 | 12 | 120,953 | 2 | 1,487,659 | 9 | 448,428 | 3 |
| Other | 110,052 | 2 | 172,029 | 3 | 728,615 | 4 | 585,043 | 4 |
| Total | \$5,888,277 | 100 | \$5,457,377 | 100 | \$17,255,916 | 100 | \$15,512,270 | 100 |

The increase of sales in Canada is due to increasing volumes with existing customers. A European customer continues to shift its manufacturing operations to the Pacific Rim.

Cost of sales was \$4,605,683 or 78.2% of sales for the three months ended September 30, 2010 as compared to \$4,576,068 or 83.9% for the same period in 2009. Cost of sales was \$13,894,697 or 80.5% for the nine months ended September 30, 2010 as compared to \$12,811,506 or 82.6% for the same period in 2009. Cost containment and reduction remains a priority of management. The increased cost of silver negatively affects margins as the higher cost increases both the revenues and cost of sales. The cost of sales excluding silver continues to improve as a result of the ongoing lean manufacturing projects and capital investment in new automated equipment. Management continues to investigate ways to improve the overall gross margin by elimination of low contribution products while increasing sales of higher margin products and investing in new equipment and technologies.

Selling and marketing expense was \$259,831 for the three months ended September 30, 2010 as compared to \$173,323 for the same period in 2009. The selling and marketing expense was 4.4% of sales in the three months ended September 30, 2010 and 3.2% for the same period in 2009. Selling and marketing expense was \$673,457 for the nine months ended September 30, 2010 as compared to \$507,501 for the same period in 2009. The selling and marketing expense was 3.9% of sales in the nine months ended September 30, 2010 and 3.3% for the same period in 2009. New business development efforts in ART including additional personnel and travel and trade show activities impacted the expense in the quarter and year to date. Costs associated with business development efforts at RMDDx contributed to increase in expense. As a percentage of sales, selling expenses are expected to increase as RMDDx accelerates its business development efforts through the remainder of 2010 and into 2011.

General and administrative expense was \$749,396 for the three months ended September 30, 2010 as compared to \$509,037 for the same period in 2009. The general and administrative expense was 12.7% of sales in the three months ended September 30, 2010 and 9.3% for the same period in 2009. General and administrative expense was \$2,025,255 for the nine months ended September 30, 2010 as compared to \$1,596,933 for the same period in 2009. The general and administrative expense was 11.7% of sales in the nine months ended September 30, 2010 and 10.3% for the same period in 2009. Approximately \$80,000 was expended in the due diligence and transactional costs in the merger and acquisition activities in the nine months ended September 30, 2010. The other increased expenses included the operational infrastructure for RMDDx, travel and other administrative expenses associated with a startup entity. As of the June 30, 2010 measurement date, the Company is not an accelerated filer; therefore, the expense related to auditor attestation for Section 404b of the Sarbanes-Oxley Act of 2002 will not be incurred in 2010.

Research and development expense was \$76,189 for the three months ended September 30, 2010 as compared to \$54,444 for the same period in 2009. The research and development expense was 1.3% of sales in the three months ended September 30, 2010 as compared to 1.0% in the same period in 2009. Research and development expense was \$179,000 for the nine months ended September 30, 2010 as compared to \$180,918 for the same period in 2009. The research and development expense was 1.0% of sales in the nine months ended September 30, 2010 and 1.2% in the same period in 2009. Approximately 35% of the expense was related to ART's SAECG software, Predictor™. The customization of the software is paid by ART's customers, and therefore is included as a cost of goods sold. The remaining portion of the research and development expense is associated with the development of a new type of electrophysiological sensor for Micron's sensor product line. This work is expected to continue through the end of 2010.

Other income (expense), net was \$(2,450) versus \$(15,291) for the three months ended September 30, 2010 and 2009, respectively. In the nine months ended September 30, 2010 other income was \$142,319 versus an expense of \$34,504. Interest income of \$9,100 and realized gains on currency translation in the period ended September 30, 2010 was offset by a loss on the disposal of assets as compared with interest income of \$8,900 offset by a gain on disposal of assets and interest expense of \$10,081 associated with an equipment note in the period ended September 30, 2009. The acquisition of RMDDx resulted in a one time non-cash gain of \$146,288 in the nine month period ended September 30, 2010 due to purchase accounting.

Income taxes as a percent of income before income taxes were 39% and 30% for the three and nine months ended September 30, 2010 as compared to 16% and 30% for the same period in 2009. The difference was primarily the result of the tax treatment of the gain from the purchase accounting, partially offset by tax credits earned or expected for the year ended December 31, 2010. Management will continue to seek to implement any tax planning opportunities that could effectively reduce the Company's income tax obligations in the future.

Liquidity and Capital Resources

Working capital was \$8,824,230 at September 30, 2010 compared to \$8,922,328 at December 31, 2009, a decrease of \$98,098. Capital investment and the dividend payments exceeded the operating cash flow. Capital investment will continue to decrease working capital with any significant investment resulting from future acquisition of assets or businesses, significant expansion of production capacity, a medical study, or further software development. Additionally, capital investment in manufacturing equipment and medical devices is expected to reduce working capital over the near term.

Accounts receivable remained higher than normal as of the end of the first three quarters of 2010. The higher than normal balance is not the result of material changes in terms or collections but rather distribution of sales during the quarter. The timing of the Company's sales continues to be highest in the third month of the quarter instead of a historically even distribution.

Net capital expenditures were \$1,080,418 for the first nine months of 2010 as compared to \$818,701 for the same period in 2009. The largest portion of the capital expenditures in first nine months of 2010 resulted from the routine replacement and upgrade of production equipment and tooling on the sensor product line. Capital expenditures for the nine months ended September 30, 2010 were made with cash on hand.

The Company's subsidiary, RMDDx, has \$515,562 in cash which is restricted as it collateralizes a guarantee on a stand-by letter of credit related to a Canadian Federal contracting economic incentive program involving an unrelated third party.

The Company has an unsecured \$2,000,000 credit line with a large multinational bank. The agreement provides for borrowings up to 80% of eligible accounts receivable plus 50% of raw material and finished goods inventories. This facility has no borrowing base charge. The agreement contains covenants that apply upon drawing on the line. The covenants relate to various matters including notice prior to executing further borrowings and security interests, merger or consolidation, acquisitions, guarantees, sales of assets other than in the normal course of business, leasing, changes in ownership and payment of dividends. No funds have been drawn down on the line as of September 30, 2010.

On December 31, 2009, the Company received a reimbursement of \$677,810 for a sale lease-back transaction related to new production equipment installed during the second half of 2009. This arrangement included a lease line with a credit limit of \$1,000,000. The Company used the remaining \$322,190 for the purchase of certain production equipment in the first nine months of 2010. The lease has a term of five years.

The Company expects to meet cash demands for its operations at current levels with current operating cash flows for the foreseeable future.

During the quarter ended September 30, 2010, the Board of Directors declared and paid a cash dividend of \$0.06 per share for a total of \$175,133. The Company has paid dividends totaling \$336,461 during the nine months ended September 30, 2010.

In October 2008, the Company's Board of Directors authorized the repurchase in the open market from time to time of up to \$650,000 of the Company's outstanding stock. To date an aggregate of 36,199 shares were purchased under the program for an aggregate of \$87,163. No purchases were made in the first nine months of 2010.

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with generally accepted accounting principles requires management to make judgments, assumptions and estimates that affect the amounts reported. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.

A critical accounting policy is defined as one that is both material to the presentation of the Company's financial statements and requires management to make difficult, subjective, and complex judgments that could have a material effect on the Company's financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: 1) the Company is required to make assumptions about matters that are highly uncertain at the time of the estimate; and 2) different estimates the Company could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on the Company's financial condition or results of operations.

Estimates and assumptions about future events and their effects cannot be determined with certainty. The Company bases its estimates on historical experience and on various other assumptions believed to be applicable and reasonable in the circumstances. These estimates may change as new events occur, as additional information is obtained and as the Company's operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, management is periodically faced with uncertainties, the outcomes of which are not within its control and will not be known for prolonged periods of time. These uncertainties are discussed in the section above entitled "Forward-looking Statements." Based on a critical assessment of its accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that the Company's consolidated financial statements are fairly stated in accordance with generally accepted accounting principles, and present a meaningful presentation of the Company's financial condition and results of operations.

Management believes that the following are critical accounting policies:

Revenue Recognition and Accounts Receivable

The Company recognizes revenue upon product shipment or customer acceptance of completion of service provided, with persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability of the related receivable is reasonably assured. The acceptance of the service for RMDDx is expected to be the prearranged transmission of medical records into the customer owned database.

Products are shipped to the customer with the warranty that the product meets the mutually agreed specifications as detailed on the purchase order. Upon agreement within 90 days of shipment between the Company and customer that the product did not conform to the agreed upon specifications, a return is authorized, credited and product returned is replaced.

The Company recognizes software license revenue upon completion of performance obligations by the company, and evidence of licenses transmitted from the control of the company.

Based on management's on-going analysis of accounts receivable balances, and after the initial recognition of the revenue, as to any event that adversely affects the ultimate ability to collect the related receivable, management will record an allowance for bad debts. Bad debts have not had a significant impact on the Company's financial position, results of operations and cash flows.

Stock-Based Compensation

The Company accounts for share based compensation under ASC 718, "Stock Compensation" ("ASC 718"). ASC 718 requires that companies recognize and measure compensation expense for all share-based payments at the grant date based on the fair market value of the award. This share-based compensation expense must be included in the Company's statement of operations over the requisite service period.

The Company uses the Black-Scholes option pricing model which requires extensive use of financial estimates and accounting judgment, including the expected volatility of the Company's common stock over the estimated term, and estimates on the expected time period that employees will retain their vested options prior to exercising them. The use of alternative assumptions could produce significantly different estimates of the fair value of the stock-based compensation and as a result, provide significantly different amounts recognized in the Company's statement of income.

Inventory and Inventory Reserves

The Company values its inventory at the lower of average cost or market. The Company reviews its inventory for quantities in excess of production requirements, obsolescence and for compliance with internal quality specifications. Any adjustments to inventory would be equal to the difference between the cost of inventory and the estimated net market value based upon assumptions about future demand, market conditions and expected cost to distribute those products to market.

The Company maintains some reserve for excess, slow moving, and obsolete inventory. A review of inventory on hand is made at least annually and some obsolete inventory is scrapped and/or recycled. The review is based on several factors including a current assessment of future product demand, historical experience, and product expiration.

Deferred Tax Assets

The Company assesses its deferred tax assets based upon a more likely than not to be realized criteria. The Company considers future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance. In accordance with ASC 740 we recognize the benefits of a tax position if that position is more likely than not to be sustained on audit, based on the technical merit of the position.

Asset Impairment – Goodwill

The Company reviews the valuation of goodwill and intangible assets to assess potential impairments. Management reassesses the useful lives of other intangible assets with identifiable useful lives in accordance with the guidelines set forth in ASC 350, “Intangible Assets”. The value assigned to intangible assets is determined by a valuation based on estimates and judgment regarding expectations for the success and life cycle of products previously acquired or others likely to be acquired in the future. If the actual sale of product and market acceptance differs significantly from the estimates, management may be required to record an impairment charge to write down the asset to its realizable value. To test for impairment, a present value of an estimate of future cash flows related to goodwill or intangible assets with indefinite lives are calculated and compared to the value of the intangible asset during the first quarter annually. When impairment exists it could have a material adverse effect on the Company’s business, financial condition and results of operations. Annual testing was completed on March 31, 2010 and no impairment of goodwill was required.

Asset Impairment – Long Lived Assets

The Company assesses the impairment of long-lived assets and intangible assets with finite lives whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. When the Company’s management determines that the carrying value of such assets may not be recoverable, management generally measures any impairment on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in its current business model.

Foreign Operations and Currency Translation

Accounts of our foreign subsidiary are recorded using its local currency (CAD) as the functional currency. For consolidation purposes, our foreign subsidiary’s (1) income statement accounts are converted to U.S. dollars using the average exchange rate for the period being reported, (2) assets and liabilities are converted to U.S. dollars using the exchange rate in effect as of the balance sheet date and (3) equity transactions are converted to U.S. dollars using the exchange rate in effect as of the date of the transaction. The resulting translation gains and losses are reported as a component of accumulated other comprehensive income or loss. Gains and losses resulting from transactions which are denominated in other than the functional currencies are reported as other, net in the statements of income in the period the gain or loss occurred.

Item 3. Quantitative and Qualitative Disclosure About Market Risks

Not applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report, the Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer (“the Certifying Officers”), conducted evaluations of the Company’s disclosure controls and procedures as defined under Sections 13a – 15(e) and 15d – 15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, the Certifying Officers have concluded that the Company’s disclosure controls and procedures were effective to ensure that material information is recorded, processed, summarized and reported by management of the Company on a timely basis in order to comply with the Company’s disclosure obligations under the Exchange Act and the rules and regulations promulgated thereunder.

Changes in Internal Control over Financial Reporting

Further, there were no changes in the Company's internal control over financial reporting during the Company's third fiscal quarter that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II - OTHER INFORMATION

Item 7. Exhibits

(a) Exhibits

3.0 Articles of Incorporation(a)

Amended and Restated By-laws(b)

3.1

10.43* Employment agreement between James E. Rouse and the Company dated December 26th, 2006.(c)

10.44* Employment agreement between David A. Garrison and the Company dated January 1st, 2007.(d)

31.1 Certification of the CEO pursuant to Rule 13a-14(a) or Rule 15(d)-14(a) on page X-1.

31.2 Certification of the CFO pursuant to Rule 13a-14(a) or Rule 15(d)-14(a) on page X-2.

32.1 Certification pursuant to 18 U.S.C. §1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 on page X-3.

32.2 Certification pursuant to 18 U.S.C. §1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 on page X-4.

* Indicates a management contract or compensatory plan required to be filed as an exhibit.

(a) Incorporated by reference from the Company's Registration Statement on Form S-18 as filed with the Commission in April 1988, Registration Statement No. 33-20945-FW.

(b) Incorporated by reference from the Company's Form 8-K as filed with the Commission May 8, 2009.

(c) Incorporated by reference from the Company's Form 8-K as filed with the Commission on December 8, 2006.

Incorporated by reference from the Company's Form 10-KSB for period ended December 31, 2006 as filed with (d) the Commission in March of 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ARRHYTHMIA RESEARCH TECHNOLOGY,
INC.

November 10, 2010

By: /s/ James E. Rouse
James E. Rouse
President and Chief Executive Officer

(Principal Executive Officer)

By: /s/ David A. Garrison
David A. Garrison
Executive Vice President and Chief Financial
Officer
(Principal Financial and Accounting Officer)

Index to Exhibits

| Number | Exhibit | Page |
|-------------|--|------|
| <u>31.1</u> | Certification of the CEO pursuant to Rule 13a-14(a) or Rule 15(d)-14(a) | X-1 |
| <u>31.2</u> | Certification of the CFO pursuant to Rule 13a-14(a) or Rule 15(d)-14(a) | X-2 |
| <u>32.1</u> | Certification pursuant to 18 U.S.C. §1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X-3 |
| <u>32.2</u> | Certification pursuant to 18 U.S.C. §1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X-4 |